Research programme: protein therapeutics - Complix

Drug Profile

Research programme: protein therapeutics - Complix

Alternative Names: Alphabodies; Alphabody; Anti-MCL1 alphabody; Cell-penetrating alphabodies; CMPX 1023; CMX-02; CPABs - Complix

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Complix
  • Class Proteins
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Interleukin-23 subunit p19 modulators; MCL1 protein modulators; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Viral infections

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer
  • No development reported CNS disorders; Metabolic disorders; Viral infections

Most Recent Events

  • 19 Dec 2017 Comlpix has patent protection for Alphabody™platform and Cell Penetrating Alphabodies™
  • 19 Dec 2017 Preclinical trials in Autoimmune disorders in Belgium (Parenteral)
  • 29 Nov 2016 Protein therapeutics are still in preclinical trials for Cancer in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top